FCGR3A

Gene

Fc gamma receptor IIIa

HGNCHGNC:3619 EnsemblENSG00000203747 NCBI Gene2214

Locus: gene with protein productLocation: 1q23.3

Encodes

via encodes

The protein product this gene encodes, reached through the canonical GENE→PROTEIN (encodes) relation. Its biology, drugs, indications, trials and therapeutic evidence live on the protein's own page.

Low affinity immunoglobulin gamma Fc region receptor III-AP08637

Protein · therapeutic target

Clinical-stage target · 2 candidates in clinical development

Explore protein biology & therapeutics

Also known as

Symbols and names change; identity (the HGNC ID) does not. Previous and alternative forms are kept distinct.

Also known asFCGR3 · FCG3 · CD16 · CD16a · FcgammaRIIIa · FcGRIIIA

View full nomenclature history (9)

Previous symbolsFCGR3, FCG3

Alias symbolsCD16, CD16a, FcgammaRIIIa, FcGRIIIA

Previous namesFc fragment of IgG, low affinity IIIa, receptor for (CD16), Fc fragment of IgG, low affinity IIIa, receptor (CD16a), Fc fragment of IgG receptor IIIa

Associated diseases

via associated_with

Diseases linked to this gene through the canonical GENE→DISEASE (associated_with) relation, drawn from Open Targets' top-ranked associations by overall score — not the full association set. Disease-level detail lives on each disease's own page.

Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity

Leishmaniasis, Cutaneous

Stomach Neoplasms

Takayasu arteritis

Arthritis, Rheumatoid

Carcinoma, Squamous Cell

Neoplasms

immunoglobulin G4-related sclerosing disease

Drawn from Open Targets’ top 10 associations by overall score for this gene — the subset resolved to a canonical disease. Lower-ranked associations, and diseases not yet canonicalised, are not shown.

Gene family

HGNC gene-group membership.

CD moleculesImmunoglobulin like domain containingFc receptors

Provenance

HGNCCanonical human gene identity from HGNC (release 2026-07-07), updated 2023-01-20.

Open TargetsGene–disease associations from the Open Targets Platform.